Several interesting combinations of therapies with Calquence for patients with CLL
Calquence, acalabrutinib, is a specific inhibitor of Bruton tyrosine kinase and a very effective and well-tolerated drug in treating CLL. At this year’s ASH Congress, several studies of combination therapies were presented, showing, according to Matthew Davids, that acalabrutinib will be a part of the combinations in the future. In this MEDtalk, Matthew Davids from the Dana Faber Cancer Institute in Boston, USA, gives his perspective on the combinations with acalabrutinib.
Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.